Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336479 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT00336479 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 263 participants.
The verdict
NCT00336479, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
Interventions
- OTHER Placebo
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG Pegylated Interferon Alfa 2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336479
The ClinicalTrials.gov registry entry for NCT00336479 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00336479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336479 about?
NCT00336479 is a clinical study titled "Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C". Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
What is the current status of trial NCT00336479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2006-06. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00336479?
The interventions under investigation include: Placebo (OTHER), Ribavirin (DRUG), Telaprevir (DRUG), Pegylated Interferon Alfa 2a (DRUG).
Who is sponsoring clinical trial NCT00336479?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.